Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.08. | Inhibikase taps commercial chief from Pfizer, Gilead to pave the way for PAH launch | 30 | FiercePharma | ||
19.08. | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 258 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
15.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 | 1 | Seeking Alpha | ||
14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.08. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.08. | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 114 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ABBVIE | 179,60 | -0,22 % | AbbVie's RINVOQ Secures Health Canada's Approval For Giant Cell Arteritis Treatment | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in... ► Artikel lesen | |
TEVA | 15,800 | +0,32 % | Neues Abnehmmittel kommt!: Vorsicht Novo Nordisk & Eli Lilly - Teva bringt "Abnehm-Generika" auf US-Markt! | Novo Nordisk und Eli Lilly bekommen Konkurrenz: Teva steigt mit einem Generikum in den US-Markt für Abnehmpräparate ein. Mit der FDA-Zulassung steigt der israelische Pharmariese in den milliardenschweren... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 10,040 | +1,48 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
ORGANIGRAM GLOBAL | 1,500 | +1,35 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
QUANTUM BIOPHARMA | 14,000 | -2,10 % | Quantum BioPharma Announces Corporate Updates | TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 5,750 | +8,49 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
AMARIN | 13,000 | +0,78 % | Amarin Corporation plc: New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 | ||
NEKTAR THERAPEUTICS | 25,200 | -1,56 % | Nektar Therapeutics Reports Second Quarter 2025 Financial Results | SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025.
Cash... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 108,60 | -0,55 % | Jazz Pharmaceuticals stock price target raised to $205 by Truist Securities | ||
SELLAS LIFE SCIENCES | 1,634 | -0,24 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
XORTX THERAPEUTICS | 0,726 | +5,52 % | XORTX gibt 3-Millionen-USD-Platzierung bekannt | - Erlös wird für die Weiterentwicklung der XORTX-Programme zur Gichtbehandlung verwendet -
CALGARY, AB, 19. Mai 2025 / IRW-Press / XORTX Therapeutics Inc. ("XORTX" oder das "Unternehmen")... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 372,00 | -0,56 % | Madrigal Pharmaceuticals: Ein möglicher Favorit unter den Biotech-Aktien? | Die Aktie von Madrigal Pharmaceuticals zeigt seit Wochen eine deutliche Aufwärtsbewegung. Könnte das Biotech-Unternehmen vom neuen Branchentrend profitieren Den vollständigen Artikel lesen ... ► Artikel lesen | |
BRIDGEBIO PHARMA | 44,010 | -0,16 % | BridgeBio Pharma, Inc.: BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 | ||
OPUS GENETICS | 1,010 | -3,63 % | Opus Genetics schließt Privatplatzierung über 3,5 Millionen US-Dollar ab | ||
VERONA PHARMA PLC ADR | 90,20 | -0,44 % | Aktie von Verona Pharma auf Rekordhoch vor Merck-Übernahme |